Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HPPH in Esophageal Cancer
NCT03757754Phase 1Unknown
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- Jun 2015
- Primary completion
- Jan 2019
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of hpph in esophageal cancer (6 arms), sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd. Primary endpoint: Dose-Limiting Toxicity. Status: unknown.
02
Drugs
hpph
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03757754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03757754.